Reuters logo
BRIEF-Protalix Biotherapeutics enrolls first patient in Phase II clinical trial of OPRX-106
November 30, 2016 / 12:46 PM / a year ago

BRIEF-Protalix Biotherapeutics enrolls first patient in Phase II clinical trial of OPRX-106

Nov 30 (Reuters) - Protalix Biotherapeutics Inc

* Protalix Biotherapeutics enrolls first patient in Phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis

* Protalix Biotherapeutics enrolls first patient in Phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis

* Protalix Biotherapeutics Inc - “we look forward to announcing Phase II data from our AIR DNase clinical program around year-end”

* Protalix Biotherapeutics Inc - look forward to announcing data from OPRX-106 Phase II clinical trial in second half of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below